BACKGROUND AND PURPOSE: The DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3) randomized clinical trial demonstrated the efficacy of endovascular therapy in treating ischemic stroke 6 to 16 hours after onset, resulting in better functional outcomes than standard medical therapy alone. The objective of this secondary analysis is to analyze the effect of late-window endovascular treatment of ischemic stroke on quality of life (QoL) outcomes. METHODS: Patients (n=182) who presented between 6 and 16 hours after they were last known to be well with acute anterior circulation ischemic stroke were randomized to endovascular thrombectomy plus standard medical therapy or standard medical therapy alone and followed-up through 90 days poststroke. QoL at day 90 was assessed with the QoL in Neurological Disorders measurement tool. RESULTS: Of the 146 subjects alive at day 90, 136 (95%) filled out QoL in Neurological Disorders short forms. Patients treated with endovascular therapy had better QoL scores in each domain: mobility, social participation, cognitive function, and depression (P<0.01 for all). Variables other than endovascular therapy that were independently associated with better QoL included lower baseline National Institutes of Health Stroke Scale, younger age, and male sex. The degree to which the modified Rankin Scale captures differences in QoL between patients varied by domain; the modified Rankin Scale score accounted for a high proportion of the variability in mobility (Rs2=0.82), a moderate proportion in social participation (Rs2=0.62), and a low proportion in cognition (Rs2=0.31) and depression (Rs2=0.19). CONCLUSIONS: Patients treated with endovascular therapy 6 to 16 hours after stroke have better QoL than patients treated with medical therapy alone, including better mobility, more social participation, superior cognition, and less depression. The modified Rankin Scale fails to capture patients' outcomes in cognition and depression, which should therefore be assessed with dedicated QoL tools. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02586415.
BACKGROUND AND PURPOSE: The DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3) randomized clinical trial demonstrated the efficacy of endovascular therapy in treating ischemic stroke 6 to 16 hours after onset, resulting in better functional outcomes than standard medical therapy alone. The objective of this secondary analysis is to analyze the effect of late-window endovascular treatment of ischemic stroke on quality of life (QoL) outcomes. METHODS: Patients (n=182) who presented between 6 and 16 hours after they were last known to be well with acute anterior circulation ischemic stroke were randomized to endovascular thrombectomy plus standard medical therapy or standard medical therapy alone and followed-up through 90 days poststroke. QoL at day 90 was assessed with the QoL in Neurological Disorders measurement tool. RESULTS: Of the 146 subjects alive at day 90, 136 (95%) filled out QoL in Neurological Disorders short forms. Patients treated with endovascular therapy had better QoL scores in each domain: mobility, social participation, cognitive function, and depression (P<0.01 for all). Variables other than endovascular therapy that were independently associated with better QoL included lower baseline National Institutes of Health Stroke Scale, younger age, and male sex. The degree to which the modified Rankin Scale captures differences in QoL between patients varied by domain; the modified Rankin Scale score accounted for a high proportion of the variability in mobility (Rs2=0.82), a moderate proportion in social participation (Rs2=0.62), and a low proportion in cognition (Rs2=0.31) and depression (Rs2=0.19). CONCLUSIONS: Patients treated with endovascular therapy 6 to 16 hours after stroke have better QoL than patients treated with medical therapy alone, including better mobility, more social participation, superior cognition, and less depression. The modified Rankin Scale fails to capture patients' outcomes in cognition and depression, which should therefore be assessed with dedicated QoL tools. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02586415.
Entities:
Keywords:
cognitive dysfunction; depression; endovascular procedures; ischemic stroke; quality of life
Authors: Lucie A van den Berg; Marcel G W Dijkgraaf; Olvert A Berkhemer; Puck S S Fransen; Debbie Beumer; Hester F Lingsma; Charles B L M Majoie; Diederik W J Dippel; Aad van der Lugt; Robert J van Oostenbrugge; Wim H van Zwam; Yvo B W E M Roos Journal: N Engl J Med Date: 2017-04-06 Impact factor: 91.245
Authors: Gregory W Albers; Michael P Marks; Stephanie Kemp; Soren Christensen; Jenny P Tsai; Santiago Ortega-Gutierrez; Ryan A McTaggart; Michel T Torbey; May Kim-Tenser; Thabele Leslie-Mazwi; Amrou Sarraj; Scott E Kasner; Sameer A Ansari; Sharon D Yeatts; Scott Hamilton; Michael Mlynash; Jeremy J Heit; Greg Zaharchuk; Sun Kim; Janice Carrozzella; Yuko Y Palesch; Andrew M Demchuk; Roland Bammer; Philip W Lavori; Joseph P Broderick; Maarten G Lansberg Journal: N Engl J Med Date: 2018-01-24 Impact factor: 91.245
Authors: Gregory W Albers; Maarten G Lansberg; Stephanie Kemp; Jenny P Tsai; Phil Lavori; Soren Christensen; Michael Mlynash; Sun Kim; Scott Hamilton; Sharon D Yeatts; Yuko Palesch; Roland Bammer; Joe Broderick; Michael P Marks Journal: Int J Stroke Date: 2017-03-24 Impact factor: 5.266
Authors: Richard C Gershon; Jin Shei Lai; Rita Bode; Seung Choi; Claudia Moy; Tom Bleck; Deborah Miller; Amy Peterman; David Cella Journal: Qual Life Res Date: 2011-08-27 Impact factor: 4.147
Authors: Arunima Kapoor; Krista L Lanctôt; Mark Bayley; Alex Kiss; Nathan Herrmann; Brian J Murray; Richard H Swartz Journal: Stroke Date: 2017-04-24 Impact factor: 7.914
Authors: G M S Nys; M J E van Zandvoort; P L M de Kort; H B van der Worp; B P W Jansen; A Algra; E H F de Haan; L J Kappelle Journal: Neurology Date: 2005-03-08 Impact factor: 9.910
Authors: Jasmin D Sanchez; Richard A Martirosian; Katherine T Mun; Davis S Chong; Irene Lorenzo Llorente; Timo Uphaus; Klaus Gröschel; Teresa A Wölfer; Steffen Tiedt; Jason D Hinman Journal: Front Neurol Date: 2022-05-16 Impact factor: 4.086
Authors: Kimberly S Erler; Rui Wu; Julie A DiCarlo; Marina F Petrilli; Perman Gochyyev; Leigh R Hochberg; Steven A Kautz; Lee H Schwamm; Steven C Cramer; Seth P Finklestein; David J Lin Journal: Neurology Date: 2022-03-11 Impact factor: 11.800